Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook"
Overview
Public Health
Affiliations
Background: To develop a knowledge translation (KT) tool that will provide guidance to stakeholders actively planning or considering implementation of a health technology reassessment (HTR) initiative.
Methods: The KT tool is an international and collaborative endeavour between HTR researchers in Canada, Australia, and the United Kingdom. Evidence from a meta-review of documented international HTR experiences and approaches provided the conceptual framing for the KT tool. The purpose, audience, format, and overall scope and content of the tool were established through iterative discussions and consensus. An initial version of the KT tool was beta-tested with an international community of relevant stakeholders (i.e., potential users) at the Health Technology Assessment International 2018 annual meeting.
Results: An open access workbook, referred to as the HTR playbook, was developed. As a KT tool, the HTR playbook is intended to simplify the complex HTR planning process by navigating users step-by-step through 6 strategic domains: characteristics of the candidate health technology (), stakeholders to engage (), potential facilitators and/or barriers within the policy context (), strategic use of different levers and tools (), unintended consequences (), and metrics and methods for monitoring and evaluation ().
Conclusion: The HTR playbook is intended to enhance a user's ability to successfully complete a HTR by helping them systematically consider the different elements and approaches to achieve the right care for the patient population in question.
Becchetti A, Martini A, Scroccaro G, Joppi R Front Pharmacol. 2024; 15:1406351.
PMID: 39166105 PMC: 11333330. DOI: 10.3389/fphar.2024.1406351.
Shin S, Kim Y, Choi J, Park J Int J Technol Assess Health Care. 2024; 40(1):e28.
PMID: 38738417 PMC: 11569900. DOI: 10.1017/S026646232400014X.
Bharmal M, Katsoulis I, Chang J, Graham A, Stavropoulou A, Jhingran P Future Oncol. 2024; 20(21):1467-1478.
PMID: 38573230 PMC: 11441014. DOI: 10.2217/fon-2023-1004.